Melanoma Institute Australia
Clinical trials sponsored by Melanoma Institute Australia, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo shows promise in shrinking skin cancer before surgery Results expected Sep 2026 (estimated)
- New immunotherapy combo aims to stop merkel cell cancer return Results expected Dec 2026 (estimated)
- Can a simple test predict who will beat skin cancer with immunotherapy? Results expected Jun 2027 (estimated)
-
Can a Triple-Drug punch before surgery beat melanoma recurrence?
Disease control OngoingThis trial is testing three different drug combinations given before surgery for advanced melanoma. The goal is to see which combination best shrinks the tumor before it is removed and helps prevent the cancer from coming back after surgery. The study involves adults with resecta…
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug cocktail aims to shrink melanoma before surgery
Disease control OngoingThis phase II trial tests two drugs, pembrolizumab and lenvatinib, given before surgery to people with stage III melanoma that can be removed. The goal is to see if the combination can shrink or eliminate the tumor before the operation. Twenty-one participants will receive the dr…
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Double immunotherapy before surgery shows promise in early melanoma
Disease control OngoingThis study tests giving two immunotherapy drugs (relatlimab and nivolumab) before surgery to people with high-risk stage II melanoma. The goal is to see if this combination can shrink or eliminate the tumor before it is removed. Twenty adults with residual disease after biopsy ar…
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Immunotherapy duo takes on brain tumors in melanoma patients
Disease control OngoingThis study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink melanoma tumors that have spread to the brain. About 76 adults with stage IV melanoma and at least one brain metastasis will receive treatment. The main goal is to see how man…
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC